Outset Medical names Brittni McGill as first Chief Nursing Officer

SAN JOSE, Calif. - Outset Medical, Inc. (NASDAQ:OM), a medical technology company with strong liquidity metrics and a current market capitalization of $311 million, has appointed Brittni McGill to the newly created position of Chief Nursing Officer, according to a press release issued Wednesday. McGill will lead clinical education and support programs for the dialysis nursing community. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt and a robust current ratio of 8.37x.

McGill joins the medical technology company after an 18-year career in nursing and hospital executive roles. She previously managed clinical services for a 350-bed hospital, overseeing more than 1,400 employees and developing multiple clinical programs.

In her prior role, McGill led her hospital’s transition from outsourced to insourced dialysis services using Outset’s Tablo system. This change reportedly increased the successful treatment rate to 98% and reduced central line blood stream infections by 75%.

"Brittni is a forward-thinking, creative and results-driven nurse executive who brings deep expertise in driving cost effective, quality driven clinical transformation," said Dr. Michael Aragon, Chief Medical Officer at Outset Medical.

McGill is currently pursuing a Doctorate of Nursing Practice at Baylor University. She holds a Master’s degree in Nursing Administration from the University of Texas at Arlington and a Bachelor’s degree in Nursing from the University of Oklahoma.

Outset Medical develops the Tablo Hemodialysis System, which is FDA-cleared for use from hospitals to homes. The company describes the system as integrating water purification and on-demand dialysate production. With the company’s next earnings report due in just 7 days, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed research reports, which include expert analysis of the company’s financial health, market position, and growth prospects.

In other recent news, Outset Medical Inc. reported a 5.6% year-over-year increase in revenue, reaching $29.8 million for the first quarter. This figure exceeded both Oppenheimer’s estimate of $28.3 million and the consensus estimate of $27.8 million. In a strategic move, Outset Medical appointed Renee Gaeta as its new Chief Financial Officer, succeeding Nabeel Ahmed. Gaeta, who previously held the CFO position at Shockwave Medical, will also manage the company’s Information Technology and Human Resources departments. BTIG analysts have maintained a Buy rating on the stock, expressing confidence in Gaeta’s leadership abilities.

Additionally, RBC Capital Markets raised its price target for Outset Medical to $21.00 from $14.00, reflecting a more optimistic valuation based on improved business performance. The company has also added healthcare veteran Kevin O’Boyle to its Board of Directors, where he will serve as chair of the Audit Committee. Oppenheimer analysts have maintained a Perform rating on the stock following these developments. Outset Medical continues to project revenues between $115 million and $125 million for 2025, with non-GAAP gross margins in the high-30% range.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.